arrow
P

Pascal Artru

Medical University of Vienna
H指数:37
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study

循环肿瘤DNA驱动抗EGFR再挑战疗法在转移性结直肠癌中的应用:RASINTRO前瞻性多中心研究

2025-09-010
PRE
Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)

基于贝伐珠单抗的化疗,根据贝伐珠单抗药代动力学适应性调整,用于不可切除性转移性结直肠癌患者的一线治疗:一项双盲、多中心、随机III期临床试验研究(PHARBEVACOL试验)

2025-05-010
OAAI
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial

TFOX与FOLFOX在HER2阴性晚期胃或胃食管结合部腺癌患者一线治疗中的比较(PRODIGE 51-FFCD-GASTFOX):一项开放标签、多中心、随机、III期临床试验

2025-04-230
PRE
Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients
2025-03-010
PRE
Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study
2024-11-010
OAAI
Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study
2024-09-014
OAAI
Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: The RASINTRO prospective multicenter study

循环肿瘤DNA驱动抗EGFR再挑战疗法在转移性结直肠癌中的应用:RASINTRO前瞻性多中心研究

2024-09-010
PRE
Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study

三联化疗加或不加贝伐单抗作为转移性结直肠癌的一线治疗: 一项AGEO多中心真实世界研究

2024-09-010
PRE
Short course radiotherapy versus radiochemotherapy for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42/GERICO 12 study): Quality of life and comprehensive geriatric assessment
2024-04-010
PRE
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies

Pemigatinib用于先前治疗过的局部晚期或转移性胆管癌患者的FGFR2融合或重排: 法国pemi-bil和意大利pemi-real队列研究的联合分析

2024-03-015
OAAI
5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD
2023-10-0115
OA
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study
2023-03-072
PRE